{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T04:38:21Z","timestamp":1794458301861,"version":"4.9.1"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.parkreldis.2025.108147","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T07:44:15Z","timestamp":1765266255000},"page":"108147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Impulse control disorders and dopamine receptor agonism in Parkinson's disease patients: Clinical implications"],"prefix":"10.1016","volume":"143","author":[{"given":"Nils M.","family":"Tangedal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7230-6426","authenticated-orcid":false,"given":"Ole-Bj\u00f8rn","family":"Tysnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.parkreldis.2025.108147_bib1","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a008862","article-title":"The history of Parkinson's disease: early clinical descriptions and neurological therapies","volume":"1","author":"Goetz","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.parkreldis.2025.108147_bib2","article-title":"Dopamine agonists in parkinson's disease: impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment","volume":"9","author":"Isaacson","year":"2023","journal-title":"Clin Park Relat Disord"},{"issue":"6","key":"10.1016\/j.parkreldis.2025.108147_bib3","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.parkreldis.2025.108147_bib4","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/mds.27668","article-title":"Impulse control disorders in Parkinson's disease: a 20-year odyssey","volume":"34","author":"Weintraub","year":"2019","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2025.108147_bib5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s00415-024-12865-5","article-title":"Impulse control disorders in Parkinson's disease: what's new?","volume":"272","author":"Marques","year":"2025","journal-title":"J. Neurol."},{"issue":"12","key":"10.1016\/j.parkreldis.2025.108147_bib6","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1001\/jamainternmed.2014.4097","article-title":"Dopamine receptor agonist drugs and impulse control disorders","volume":"174","author":"Weiss","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.parkreldis.2025.108147_bib7","article-title":"Biochemistry, dopamine receptors","author":"Bhatia","year":"2025","journal-title":"StatPearls. Treasure Island (FL)"},{"issue":"5","key":"10.1016\/j.parkreldis.2025.108147_bib8","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/archneur.61.5.641","article-title":"The neurobiology of dopamine signaling","volume":"61","author":"Girault","year":"2004","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108147_bib9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.coph.2008.12.002","article-title":"Getting specialized: presynaptic and postsynaptic dopamine D2 receptors","volume":"9","author":"De Mei","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.parkreldis.2025.108147_bib10","doi-asserted-by":"crossref","DOI":"10.1177\/1179069518779829","article-title":"Physiological and functional basis of dopamine receptors and their role in neurogenesis: possible implication for Parkinson's disease","volume":"12","author":"Mishra","year":"2018","journal-title":"J. Exp. Neurosci."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108147_bib11","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/pr.110.002642","article-title":"The physiology, signaling, and pharmacology of dopamine receptors","volume":"63","author":"Beaulieu","year":"2011","journal-title":"Pharmacol. Rev."},{"issue":"7","key":"10.1016\/j.parkreldis.2025.108147_bib12","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40265-019-01103-2","article-title":"Are all dopamine agonists essentially the same?","volume":"79","author":"Torti","year":"2019","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.parkreldis.2025.108147_bib13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.tins.2024.12.002","article-title":"Establishing functionally segregated dopaminergic circuits","volume":"48","author":"Terauchi","year":"2025","journal-title":"Trends Neurosci."},{"issue":"10","key":"10.1016\/j.parkreldis.2025.108147_bib14","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMcp043908","article-title":"Clinical practice. Diagnosis and initial management of Parkinson's disease","volume":"353","author":"Nutt","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.parkreldis.2025.108147_bib15","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/jpet.102.039867","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes","volume":"303","author":"Millan","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.parkreldis.2025.108147_bib16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00702-019-01989-y","article-title":"Classical dopamine agonists","volume":"126","author":"Horowski","year":"2019","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.parkreldis.2025.108147_bib17","series-title":"Dopamine Agonists. StatPearls","author":"Choi","year":"2025"},{"issue":"2","key":"10.1016\/j.parkreldis.2025.108147_bib18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.pharmthera.2010.06.002","article-title":"From the cell to the clinic: a comparative review of the partial D(2)\/D(3)receptor agonist and alpha2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease","volume":"128","author":"Millan","year":"2010","journal-title":"Pharmacol. Ther."},{"issue":"20","key":"10.1016\/j.parkreldis.2025.108147_bib19","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1212\/WNL.0000000000012868","article-title":"Dopaminergic therapy for motor symptoms in Early Parkinson Disease practice guideline summary: a report of the AAN guideline subcommittee","volume":"97","author":"Pringsheim","year":"2021","journal-title":"Neurology"},{"issue":"9949","key":"10.1016\/j.parkreldis.2025.108147_bib20","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0140-6736(14)60683-8","article-title":"Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial","volume":"384","author":"Group","year":"2014","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.parkreldis.2025.108147_bib21","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1002\/mds.28726","article-title":"On-demand therapy for OFF episodes in Parkinson's Disease","volume":"36","author":"Olanow","year":"2021","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.parkreldis.2025.108147_bib22","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","article-title":"Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial","volume":"17","author":"Katzenschlager","year":"2018","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.parkreldis.2025.108147_bib23","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/14737175.2025.2485337","article-title":"Managing impulse control and related behavioral disorders in Parkinson's disease: where we are in 2025?","volume":"25","author":"Rigon","year":"2025","journal-title":"Expert Rev. Neurother."},{"issue":"8","key":"10.1016\/j.parkreldis.2025.108147_bib24","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00702-018-1870-8","article-title":"Impulse control disorders in Parkinson's disease","volume":"125","author":"Marques","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.parkreldis.2025.108147_bib25","article-title":"Impulse control disorders in Parkinson's disease: epidemiology, pathogenesis and therapeutic strategies","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Psychiatr."},{"issue":"4","key":"10.1016\/j.parkreldis.2025.108147_bib26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/syn.21805","article-title":"Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors","volume":"69","author":"Seeman","year":"2015","journal-title":"Synapse"},{"issue":"6","key":"10.1016\/j.parkreldis.2025.108147_bib27","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40263-024-01087-y","article-title":"Impulse control disorders in Parkinson's disease: an overview of risk factors, pathogenesis and pharmacological management","volume":"38","author":"Carbone","year":"2024","journal-title":"CNS Drugs"},{"issue":"Suppl 2","key":"10.1016\/j.parkreldis.2025.108147_bib28","first-page":"S93","article-title":"Dopamine and impulse control disorders in Parkinson's disease","volume":"64","author":"Weintraub","year":"2008","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.parkreldis.2025.108147_bib29","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/WCO.0000000000000955","article-title":"Impulse control disorders and related behaviors in Parkinson's disease: risk factors, clinical and genetic aspects, and management","volume":"34","author":"Faouzi","year":"2021","journal-title":"Curr. Opin. Neurol."},{"issue":"4","key":"10.1016\/j.parkreldis.2025.108147_bib30","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/jnnp.68.4.423","article-title":"Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies","volume":"68","author":"Giovannoni","year":"2000","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"7","key":"10.1016\/j.parkreldis.2025.108147_bib31","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/archneur.63.7.969","article-title":"Association of dopamine agonist use with impulse control disorders in Parkinson disease","volume":"63","author":"Weintraub","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.parkreldis.2025.108147_bib32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1196\/annals.1444.006","article-title":"Impulse control and related disorders in Parkinson's disease: review","volume":"1142","author":"Lim","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.parkreldis.2025.108147_bib33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.euroneuro.2022.01.113","article-title":"Impulse control disorders associated with dopaminergic drugs: a disproportionality analysis using vigibase","volume":"58","author":"De Wit","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.parkreldis.2025.108147_bib34","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1212\/WNL.0000000000005816","article-title":"Longitudinal analysis of impulse control disorders in Parkinson disease","volume":"91","author":"Corvol","year":"2018","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.parkreldis.2025.108147_bib35","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/jnnp-2015-311827","article-title":"Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease","volume":"87","author":"Smith","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.parkreldis.2025.108147_bib36","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients","volume":"67","author":"Weintraub","year":"2010","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108147_bib37","doi-asserted-by":"crossref","first-page":"82","DOI":"10.14802\/jmd.23042","article-title":"Parkinson's Disease, impulsive-compulsive behaviors, and health-related quality of life","volume":"17","author":"Grall-Bronnec","year":"2024","journal-title":"J Mov Disord"},{"key":"10.1016\/j.parkreldis.2025.108147_bib38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.parkreldis.2020.07.007","article-title":"Impulsive and compulsive behaviors in Parkinson's disease: impact on quality of and satisfaction with life, and caregiver burden","volume":"78","author":"Erga","year":"2020","journal-title":"Park. Relat. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2025.108147_bib39","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/mds.29700","article-title":"Management of impulse control and related disorders in Parkinson's Disease: an expert consensus","volume":"39","author":"Debove","year":"2024","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2025.108147_bib40","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/ene.12646","article-title":"Impulse control disorders in Parkinson's disease: don't set your mind at rest by self-assessments","volume":"22","author":"Baumann-Vogel","year":"2015","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2025.108147_bib41","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/WNF.0000000000000202","article-title":"A multicenter comparative Study of impulse control disorder in Latin American patients with parkinson disease","volume":"40","author":"Ramirez Gomez","year":"2017","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2025.108147_bib42","article-title":"Impulse control and related behavioral disorders (ICRD) in idiopathic Parkinson's Disease treated with different dopamine agonists in Hong Kong: is any dopamine agonist better?","volume":"10","author":"Wu","year":"2024","journal-title":"Clin Park Relat Disord"},{"issue":"4","key":"10.1016\/j.parkreldis.2025.108147_bib43","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s10072-023-07254-1","article-title":"Impulse control disorders in Parkinson's disease patients treated with pramipexole and ropinirole: a systematic review and meta-analysis","volume":"45","author":"Soileau","year":"2024","journal-title":"Neurol. Sci."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108147_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-73756-z","article-title":"Non-motor symptom burden in patients with Parkinson's disease with impulse control disorders and compulsive behaviours: results from the COPPADIS cohort","volume":"10","author":"Jesus","year":"2020","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.parkreldis.2025.108147_bib45","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/jnnp-2013-306787","article-title":"Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study","volume":"85","author":"Garcia-Ruiz","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"8","key":"10.1016\/j.parkreldis.2025.108147_bib46","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/ene.13034","article-title":"A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists","volume":"23","author":"Rizos","year":"2016","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108147_bib47","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10072-023-07006-1","article-title":"Impulse control disorders in Parkinson's disease: a retrospective analysis of 1824 patients in a 12-year period","volume":"45","author":"Gunduz","year":"2024","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2025.108147_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/mdc3.70240","article-title":"Subcutaneous apomorphine infusion initiation is associated with Impulse Control disorder attenuation in advanced Parkinson's Disease patients: insights from the French NS-Park cohort","author":"Desjardins","year":"2025","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"3","key":"10.1016\/j.parkreldis.2025.108147_bib49","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/pcn.13511","article-title":"Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study","volume":"77","author":"Fusaroli","year":"2023","journal-title":"Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.parkreldis.2025.108147_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.654238","article-title":"Impulse control disorders in Parkinson's disease: from bench to bedside","volume":"15","author":"Augustine","year":"2021","journal-title":"Front. Neurosci."},{"issue":"4","key":"10.1016\/j.parkreldis.2025.108147_bib51","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s00213-020-05745-z","article-title":"Dopamine receptors regulate preference between high-effort and high-risk rewards","volume":"238","author":"Gabriel","year":"2021","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.parkreldis.2025.108147_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2022.173508","article-title":"Concurrent measures of impulsive action and choice are partially related and differentially modulated by dopamine D(1)- and D(2)-like receptors in a rat model of impulsivity","volume":"222","author":"Belles","year":"2023","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.parkreldis.2025.108147_bib53","article-title":"Aberrant striatal firing mediates impulsive decision-making in a mouse model of Parkinson's disease","author":"Zhuang","year":"2025","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.parkreldis.2025.108147_bib54","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s40263-025-01193-5","article-title":"Motor and non-motor complications following different early therapies in Parkinson's disease: longitudinal analysis of real-life clinical and therapeutic data from the French NS-PARK cohort","volume":"39","author":"Lanore","year":"2025","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108147_bib55","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/jnnp-2018-318942","article-title":"Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial","volume":"90","author":"Lee","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108147_bib56","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","article-title":"Dopamine agonists and impulse control disorders: a complex Association","volume":"41","author":"Grall-Bronnec","year":"2018","journal-title":"Drug Saf."},{"issue":"8","key":"10.1016\/j.parkreldis.2025.108147_bib57","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1007\/s00213-020-05544-6","article-title":"Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian rats","volume":"237","author":"Jimenez-Urbieta","year":"2020","journal-title":"Psychopharmacology (Berl)."},{"issue":"7","key":"10.1016\/j.parkreldis.2025.108147_bib58","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.parkreldis.2013.03.004","article-title":"Past smoking and current dopamine agonist use show an independent and dose-dependent association with impulse control disorders in Parkinson's disease","volume":"19","author":"Valenca","year":"2013","journal-title":"Park. Relat. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2025.108147_bib59","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10072-022-06485-y","article-title":"Screening for impulse control disorders in Parkinson's disease and dopamine agonist use: a study of pharmacokinetic and psychological risk factors","volume":"44","author":"Contin","year":"2023","journal-title":"Neurol. Sci."},{"issue":"2","key":"10.1016\/j.parkreldis.2025.108147_bib60","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16144","article-title":"Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease","volume":"31","author":"Staubo","year":"2024","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2025.108147_bib61","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00415-024-12870-8","article-title":"Impulse control and correlation to dopamine agonist serum concentrations in people with Parkinson's disease","volume":"272","author":"Staubo","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2025.108147_bib62","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3389\/fneur.2018.01018","article-title":"Dopaminergic neurotransmission in patients with Parkinson's disease and impulse control disorders: a systematic review and meta-analysis of PET and SPECT studies","volume":"9","author":"Martini","year":"2018","journal-title":"Front. Neurol."},{"issue":"13","key":"10.1016\/j.parkreldis.2025.108147_bib63","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1523\/JNEUROSCI.3082-17.2018","article-title":"Nigrostriatal and mesolimbic D(2\/3) receptor expression in Parkinson's Disease patients with compulsive reward-driven behaviors","volume":"38","author":"Stark","year":"2018","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.parkreldis.2025.108147_bib64","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/mds.26135","article-title":"[(1)(1)C]-(+)-PHNO PET imaging of dopamine D(2\/3) receptors in Parkinson's disease with impulse control disorders","volume":"30","author":"Payer","year":"2015","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2025.108147_bib65","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/mds.23501","article-title":"Impulsivity and compulsivity in drug-naive patients with Parkinson's disease","volume":"26","author":"Antonini","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2025.108147_bib66","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2019.06.019","article-title":"Impulse control symptoms in patients with Parkinson's disease: the influence of dopaminergic agonist","volume":"68","author":"Vargas","year":"2019","journal-title":"Park. Relat. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108147_bib67","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1212\/WNL.0000000000002803","article-title":"Augmentation and impulsive behaviors in restless legs syndrome: coexistence or association?","volume":"87","author":"Heim","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2025.108147_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocn.2025.111363","article-title":"Impulse control disorders in prolactinoma patients treated with dopamine agonists: a systematic review and meta-analysis with trial sequential analysis","volume":"138","author":"Penchev","year":"2025","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.parkreldis.2025.108147_bib69","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.parkreldis.2018.01.010","article-title":"Behavioral addictions in early-onset Parkinson disease are associated with DRD3 variants","volume":"49","author":"Castro-Martinez","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2025.108147_bib70","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.parkreldis.2016.06.005","article-title":"Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson's disease patients","volume":"30","author":"Krishnamoorthy","year":"2016","journal-title":"Park. Relat. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2025.108147_bib71","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/ene.14590","article-title":"Integrating genetic and clinical data to predict impulse control disorders in Parkinson's disease","volume":"28","author":"Jesus","year":"2021","journal-title":"Eur. J. Neurol."},{"issue":"10","key":"10.1016\/j.parkreldis.2025.108147_bib72","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/jnnp-2015-312848","article-title":"Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease","volume":"87","author":"Kraemmer","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"8","key":"10.1016\/j.parkreldis.2025.108147_bib73","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/acn3.52111","article-title":"DRD4 gene polymorphism and impulse control disorder induced by dopamine agonists in Parkinson's disease","volume":"11","author":"Torres","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"10.1016\/j.parkreldis.2025.108147_bib74","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2174\/1871527322666230331121028","article-title":"Rationale and development of Tavapadon, a D1\/D5-Selective partial dopamine agonist for the treatment of Parkinson's Disease","volume":"23","author":"Bezard","year":"2024","journal-title":"CNS Neurol. Disord.: Drug Targets"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135380202500896X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135380202500896X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T16:49:48Z","timestamp":1768841388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135380202500896X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":74,"alternative-id":["S135380202500896X"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2025.108147","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impulse control disorders and dopamine receptor agonism in Parkinson's disease patients: Clinical implications","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2025.108147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108147"}}